<DOC>
	<DOCNO>NCT00480025</DOCNO>
	<brief_summary>The purpose clinical trial demonstrate benefit immunotherapeutic product GSK1572932A give patient Non-Small Cell Lung Cancer , removal tumor . A course 13 injection administer 27 month . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>GSK1572932A Antigen-Specific Cancer Immunotherapeutic Adjuvant Therapy Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Male female patient completely resect , pathologically proven stage IB , II IIIA NSCLC . Written inform consent MAGEA3 expression screen tumor biopsy obtain patient prior shipment sample expression test ( surgical resection ) , write informed consent complete study obtain prior performance protocolspecific procedure . Patient ≥ 18 year age time signature first inform consent form . The patient 's tumor show expression MAGEA3 gene The surgical technique resection patient 's tumor anatomical , involve least lobectomy sleeve lobectomy ; The mediastinal lymph node sample do accord study protocol guideline ; The patient free metastasis , confirm negative baseline computer tomogram ( CT scan ) chest , upper abdomen CT scan MRI brain . Other examination perform clinically indicate . Note randomization take place within 8 week surgery , brain CT scan brain MRI perform 4 week surgery repeat . ECOG performance status 0 , 1 2 time randomization . Adequate bonemarrow reserve , adequate renal function adequate hepatic function assess standard laboratory criterion , define : Absolute neutrophil count ≥ 1.0 x 10E9/L Platelet count ≥ 75 x 10E9/L Serum creatinine ≤ 1.5 time Upper Limit Normal ( ULN ) ≤ 3.0 time ULN due platinum adjuvant chemotherapy Total bilirubin ≤ 1.5 time ULN Alanine transaminase ( ALAT ) ≤ 2.5 time ULN If patient female , must nonchildbearing potential , i.e . current tubal ligation , hysterectomy , ovariectomy post menopausal , childbearing potential , must practice adequate contraception 30 day prior administration study treatment , negative pregnancy test continue precaution study treatment period 2 month completion injection series . In view investigator , patient comply requirement protocol . Exclusion criteria The primary tumor remove segmentectomy wedge resection . The patient show evidence residual tumor surgery . The patient receive anticancer specific treatment , include radiotherapy , immunotherapy , chemotherapy neoadjuvant chemotherapy , except : For treatment previous malignancy allow protocol ( i.e. , nonmelanoma skin cancer carcinoma situ cervix effectively treat malignancy remission 5 year ) , Administration adjuvant platinumbased chemotherapy treatment current NSCLC allow surgery randomization . The patient previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer carcinoma situ cervix effectively treat malignancy remission 5 year highly likely cure . History allergic disease reaction likely exacerbate component study investigational product . The patient autoimmune disease , limited , multiple sclerosis , lupus , inflammatory bowel disease . Patients vitiligo exclude . The patient require concomitant treatment systemic corticosteroid , immunosuppressive agent . Note : The use prednisone , equivalent , &lt; 0.5 mg/kg/day ( absolute maximum 40 mg/day ) , inhaled corticosteroid COPD topical steroid permit . The patient receive major organ allograft . The patient know HIVpositive . The patient uncontrolled bleed disorder . The patient uncontrolled congestive heart failure hypertension , unstable heart disease ( coronary artery disease myocardial infarction ) uncontrolled arrhythmia time enrolment . The patient need home oxygenation . The patient psychiatric addictive disorder may compromise his/her ability give inform consent , comply trial procedure . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . The patient receive investigational nonregistered medicinal product study medication within 30 day precede first dose study medication , plan receive drug study period . For female patient : patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ASCI</keyword>
	<keyword>Immunotherapeutic</keyword>
	<keyword>MAGRIT</keyword>
	<keyword>Tumor antigen</keyword>
	<keyword>Non-small-cell lung cancer</keyword>
	<keyword>Adjuvant cancer therapy</keyword>
</DOC>